Ipsen’s Dysport Likely Impacted By COVID-19 In Q2, But China Sales To Return
Specialty Portfolio Drives Ipsen In First Quarter
Sales grew 9.6% at Ipsen in the first quarter, and the search for a new CEO is on track, but France’s specialty pharmaceutical company maintained its 2020 guidance suspension because of the uncertainty over the course of the COVID-19 pandemic.
You may also be interested in...
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
Italy’s Italfarmaco expects top-line data from its pivotal Phase III study of givinostat in Duchenne muscular dystrophy in the middle of next year, as the HDAC inhibitor continues to accrue data from the extension of its Phase II study.